Skip to main content

Profile: Wei Wang

Wang-Wei-Final
Wei Wang, M.D., Ph.D.
Research Associate Professor
Department of Pharmacological and Pharmaceutical Sciences
Physical Address: Science and Research Building 2, 3455 Cullen Blvd., Room 136A, Houston, TX 77204
Mailing Address: Health and Biomedical Sciences Building 2, 4849 Calhoun Road, Room 3044, Houston, TX 77204-5037

713-743-7349
wwang45@uh.edu

Education

Ph.D. (Molecular Pharmacology), Fudan University, School of Pharmacy, China

B.M. (MD equivalent) with Honor, Changzhi Medical College, China

Research Interests

Cancer Research, Biochemistry, Molecular Biology, Animal Physiology and Pharmacology, Pharmaceutical Sciences, Cancer chemotherapy, Antisense therapy and gene silencing, Regulation of oncogene and tumor suppressor gene, Disease model, Preclinical and clinical drug development, Translational research/clinical trials

Research Projects

American Cancer Society (ACS) RSG-15-009-01-CDD Wang (PI)
07/01/2015-06/30/2019
Targeting MDM2 Oncogene for Breast Cancer Therapy
This study is designed to develop a novel targeted therapy for human breast cancer.
Role: PI

NIH/NCI R01 CA 186662 Zhang (PI)
04/01/2014-02/28/2019
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy
This study is designed to determine the mechanisms for the antitumor activity of novel MDM2 inhibitors in pancreatic cancer.
Role: Co-investigator

NIH/NCI R01 CA 214019 Zhang (PI)
09/04/2017-08/31/2022
Title: Novel NFAT1-MDM2 inhibitor for breast cancer therapy
Project Goal: This study is designed to develop a novel dual-targeting (MDM2 and NFAT1) strategy for the treatment of advanced breast cancer.
Role: Co-investigator

Selected Publications

Xue B, Wang W*, Qin JJ, Nijampatnam B, Murugesan S, Kozlovskaya V, Zhang R, Velu SE, Kharlampieva E. Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes. Acta Biomater. 2017; 58:386-398. (*co-first author).

Qin JJ, Wang W*, Sarkar S, Zhang R. Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. J Control Release. 2016; 237: 101-114. (*co-first and co-corresponding author).

Qin JJ, Wang W*, Sarkar S, Voruganti S, Agarwal R, Zhang R. Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy. Oncotarget. 2016; 7:32566-32578.  (*co-first and co-corresponding author)

Wang W*, Nijampatnam B, Velu SE, Zhang R. Discovery and Development of Synthetic Tricyclic Pyrroloquinone (TPQ) Alkaloid Analogs for Human Cancer Therapy. Front Chem Sci Eng. 2016; 10:1-15. (*co-first author)

Wang W, Nag S, Zhang R. Pharmacodynamics and Pharmacokinetics of Anticancer Agents in Breast Cancer Models. Methods Mol. Biol. 2016; 1406:271-87.

Voruganti S, Xu F, Qin JJ, Guo Y, Sarkar S, Gao M, Zheng Z, Wang MH, Zhou J, Qian B, Zhang R, Wang W*. RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy. Cancer Lett. 2015; 369:386- 395. (*co-corresponding author)

Qin JJ, Wang W*, Voruganti S, Wang H, Zhang WD, Zhang R. Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA. Oncotarget. 2015; 6:33106-33119. (*co-first and co-corresponding author)

Wang W, Qin JJ, Voruganti S, Nag S, Zhou J, Zhang R. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med. Res. Rev. 2015; 35:1220-1267.

Yu JX, Voruganti S, Li DD, Qin JJ, Nag S, Xu S, Velu SE, Wang W*, Zhang R. Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats. Chin J Nat Med. 2015; 13:554-560.

Wang W, Cheng J, Zhu Y. The JNK Signaling Pathway Is a Novel Molecular Target for SPropargyl- L-Cysteine, a Naturally-Occurring Garlic Derivatives: Link to Its Anticancer Activity in Pancreatic Cancer In vitro and In vivo. Curr Cancer Drug Targets. 2015; 15:613-623.

Qin JJ, Wang W*, Voruganti S, Wang H, Zhang WD, Zhang R. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. Oncotarget. 2015; 6:2623-2640. (*co-first author)

Voruganti S, Qin JJ, Sarkar S, Nag S, Walbi IS, Wang S, Zhao YQ, Wang W*, Zhang R. Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action. Oncotarget. 2015; 6:21379-21394. (*co-corresponding author)

Wang W*, Nag S, Zhang R. Targeting NF-κB signaling for breast cancer prevention and therapy. Curr Med Chem. 2015; 22:264-289. (*co-corresponding author)

Wang W, Nag S, Zhang X, Wang MH, Wang H, Zhou J, Zhang R. Ribosomal Proteins and Human Diseases: Pathogenesis, Molecular Mechanisms, and Therapeutic Implications. Med Res Rev. 2015; 35:225-285.

Nag S, Qin JJ, Voruganti S, Wang MH, Buolamwini JK, Wang W*, Zhang R. Development and validation of a UPLC method for quantitation of SP-141, a novel pyrido[b]indole antianticancer agent, and an initial pharmacokinetic study in mice. Biomed Chromatogr. 2015; 29: 654-663. (*co-corresponding author)

Wang W, Cheng J, Qin JJ, Voruganti S, Nag S, Fan J, Gao Q, Zhang R. RYBP expression is associated with the survival of patients in hepatocellular carcinoma, and regulates tumor cell growth and the response to chemotherapy in vitro and in vivo. Oncotarget. 2014; 5:11604- 11619.

Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Zhou J, Wang H, Mukhopadhyay D, Buolamwini JK, Zhang R. The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Nat.Commun. 2014; 5:5086.

Nag S, Qin JJ, Voruganti S, Wang MH, Buolamwini JK, Wang W*, Zhang R. Development and validation of an LC-MS/MS method for quantitation of SP141, a novel anti-pyrido[b]indole anticancer agent, and its application to a mouse PK study. J Chromatogr B. 2014; 969C:235- 240. (*co-corresponding author)

Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Zhou J, Wang H, Mukhopadhyay D, Buolamwini JK, Zhang R. Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice. Gastroenterology. 2014; 147:893-902.

Nag S, Zhang X, Srivenugopal KS, Wang M-H, Wang W*, Zhang R. Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet? Curr Med Chem. 2014; 21:553-574. (*co-corresponding author)

Abstracts and Presentations

Invited Presentations

Wang W. Global Summit on Genitourinary Malignancies: Invited Speech: HDM2 inhibitors and loss of p53 function. Banff, Alberta, Canada. October 22-25, 2015

Poster Presentations

Wang W, Zhang R. Targeting NFAT1-MDM2-p53 Pathway for Cancer Therapy. AACR-NCIEORTC International Conference on Molecular Targets and Cancer Therapeutics, Munich, Germany, November 29-December 2, 2016.

Wang W, Voruganti S, Qin JJ, Qian B, and Zhang R. RYBP predicts survival of patients with non-small cell lung cancer and sensitizes chemotherapy. Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November 5-9, 2015.

Wang W, Voruganti S, Qin J, Nag S, Qian B, Zhang R. Involvement of RYBP in Growth and Response to Chemotherapy in Non-small Cell Lung Cancer. Presented at the 15th SCBA International Symposium. Taipei. June 26-29, 2015.
Voruganti S, Qin JJ, Wang W, Zhang R. The anticancer activity of Japonicone A is mediated by inhibiting NFAT1-MDM2 pathway. Presented at AACR annual meeting, Philadelphia, PA, April 18-22, 2015.

Qin JJ, Wang W, Voruganti S, Zhang R. A novel MDM2 inhibitor suppresses breast cancer growth and metastasis. Presented at AACR annual meeting, Philadelphia, PA, April 18-22, 2015.

Wang W, Chen J, Qin JJ, Voruganti S, Nag S, Fan J, Gai Q, Zhang R. RYBP Expression Predicts Survival of Patients with Hepatocellular Carcinoma, and Regulates Response to Chemotherapy. Presented at AACR annual meeting, Philadelphia, PA, April 18-22, 2015.

Patents

Novel Ginsenoside Compounds Compositions and Methods of Use (U.S. patent application Serial No. 60/870,250; filed 12-15-2006)

Marine alkaloid makaluvamines and derivatives thereof (U.S. patent application Serial No. 60/891,250; filed 2-23-2007; amended 2-23-2008)

1-Aryl-OR 1-heteroaryl-pyrido[b]indoles and uses thereof (U.S. patent application Serial No. 12/799,485; filed 4-26-2010; USPTO Publishing Date: 12-16-2010; #2010/0317667A1)

Professional Memberships, Service & Appointments

Memberships
  • American Association for Cancer Research, 2005-Present
  • American Association of Pharmaceutical Scientists, 2010-Present
  • American Association for the Advancement of Science, 2010-Present
Editorial Appointments
  • Editorial Boards: Journal of Bioequivalence & Bioavailability; BioMed Research International; Journal of Pharmaceutics, Drug Delivery & Safety; Austin Pharmacology & Pharmaceutics; Journal of Cancer Clinical Trials
  • Book Reviewer Editor, Current Cancer Drug Targets